# IPCA Labs share price today (Ipca Laboratories Ltd, NSE: IPCALAB) > IPCA Labs share price today: ₹1,854.10 at the NSE close on 18 November 2026, up 28.4% in a year. Ipca Laboratories (NSE: IPCALAB) is worth ₹47,039 crore, trades at a P/E of 33.5 and has closed between ₹1,404.00 and ₹2,009.60 over the past 52 weeks. > Ipca Laboratories Ltd's results are improving, while its P/E is near the low end of its own history over 11 years, higher than only 35% of past readings. IPCALAB · Pharma - Formulators · data as of 18 November 2026. Page: https://www.sectoralpha.in/stocks/ipca-laboratories-ltd Our full read on IPCA Labs, including whether management kept its promises and what could stop it, is in the Sector Alpha newsletter: https://newsletter.sectoralpha.in/p/deep-dive-why-ipca-laboratories-is?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Business trend: Growing steadily, from fewer quarters than usual - Price: ₹1,854.10 (+28.4% in a year) - P/E: 33.5× (lower than 65% of the last 11 years) - Revenue (Sep 2026): ₹2,910 Cr (+13.8% on a year ago) - Profit (Sep 2026): ₹389 Cr (+38.4% on a year ago) - Operating margin: 23.1% (+1.8 points on a year ago) - ROCE: 17%, FY26 - Profit that came in as cash: 137%, last 3 years The main question: yearly earnings per share moved +54.7% while the share price moved +28.4%. ## What is the IPCA Labs share price today? Ipca Laboratories Ltd's share price was ₹1,854.10 at the close on 18 November 2026. It has been rising for 45 weeks. That is 6.4% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,404 and ₹2,010, and at that close it sat 74% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 2 weeks running. Over the last 11 years the share price moved +542% while the NIFTY 500 moved +280%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 8 November 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at IPCA Labs this quarter? Three changes stood out: revenue up on a year earlier for 13 quarters in a row (every quarter we can compare), profit up on a year earlier for 10 quarters in a row and foreign funds (FIIs) raised their stake for 4 quarters in a row. 1. Revenue up on a year earlier for 13 quarters in a row (every quarter we can compare) In the September 2026 quarter revenue was ₹2,910 crore, +13.8% on a year earlier. Why: Exports of the company's own generic medicines rose strongly. Next results: check whether overall business growth stays in the 14% to 16% range management kept. From the earnings call on 5 Nov 2026. 2. Profit up on a year earlier for 10 quarters in a row In the September 2026 quarter profit was ₹389 crore, +38.4% on a year earlier. Why: The UK business moved from a loss to a profit. Next results: check whether Unichem's profit margin stays in the 11% to 13% range when freight and energy costs stay high. From the earnings call on 5 Nov 2026. 3. Foreign funds (FIIs) raised their stake for 4 quarters in a row From 10.4% to 11.5% of the company by the September 2026 quarter. ## What are IPCA Labs' latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), IPCA Labs reported revenue of ₹2,910 crore, up 13.8% from ₹2,556 crore a year earlier, and a profit of ₹389 crore, up 38.4% from ₹281 crore. ### IPCA Labs results: July to September 2026 against a year earlier | Measure | July to September 2026 | July to September 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹2,910 crore | ₹2,556 crore | +13.8% | | Profit | ₹389 crore | ₹281 crore | +38.4% | | Earnings per share | ₹14.79 | ₹11.14 | +32.8% | | Operating margin | 23.1% | 21.3% | +1.8 points | The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). IPCA Labs' management discussed these results on a call held on 5 November 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.) ## What is the IPCA Labs share price history? IPCA Labs closed at ₹1,854.10 on 18 November 2026, up 28.4% from ₹1,444.00 a year earlier (21 November 2025) and up 78.5% over five years. Its highest weekly close since March 2016 was ₹2,009.60 on 18 September 2026. ### IPCA Labs share price: then and now | When | Close | Change to 18 Nov 2026 | | --- | --- | --- | | 1 week ago · 11 Nov 2026 | ₹1,938.40 | −4.3% | | 1 month ago · 19 Oct 2026 | ₹1,814.50 | +2.2% | | 6 months ago · 15 May 2026 | ₹1,605.00 | +15.5% | | 1 year ago · 21 Nov 2025 | ₹1,444.00 | +28.4% | | 3 years ago · 17 Nov 2023 | ₹1,081.05 | +71.5% | | 5 years ago · 18 Nov 2021 | ₹1,038.58 | +78.5% | | 10 years ago · 18 Nov 2016 | ₹271.50 | +582.9% | | Earliest weekly close in our records · 4 Mar 2016 | ₹288.75 | +542.1% | | Highest weekly close since March 2016, also the 52-week high · 18 Sep 2026 | ₹2,009.60 | −7.7% | | Lowest weekly close since March 2016 · 11 Aug 2017 | ₹204.73 | +805.6% | | 52-week low (weekly close) · 2 Jan 2026 | ₹1,404.00 | +32.1% | Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (568 weekly closes from 4 March 2016 to 18 November 2026.) ## What is the latest news on IPCA Labs? 18 Nov 2026: IPCA Labs closed at ₹1,854.10, down 4.3% on the week and up 2.2% on the month. 5 Nov 2026: IPCA Labs held its results call for July to September 2026. Management guided: FY27 overall business growth 14-16% retained, later referenced as 15-16%. ### Earlier - Results for July to September 2026: Revenue up 13.8% and profit up 38.4% on a year earlier. - 7 Aug 2026: ex-date for a dividend of ₹6 a share. ## What dividend does IPCA Labs pay? IPCA Labs paid ₹6 a share in regular dividends in the 12 months to 18 November 2026 (1 payment), a yield of 0.32% at the ₹1,854.10 close on 18 November 2026. The last was a dividend of ₹6 a share, ex-date 7 August 2026. ### IPCA Labs dividends since 1 April 2021 | Ex-date | Dividend per share | Type | Record date | | --- | --- | --- | --- | | 7 Aug 2026 | ₹6 | Dividend | same day | | 5 Aug 2025 | ₹2 | Dividend | same day | | 27 Nov 2024 | ₹2 | Interim | same day | | 6 Aug 2024 | ₹2 | Dividend | n/a | | 22 Nov 2023 | ₹2 | Interim | same day | | 22 Nov 2022 | ₹4 | Interim | 23 Nov 2022 | | 22 Nov 2021 | ₹8 | Interim | 23 Nov 2021 | Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record Not in its latest year. Ipca Laboratories Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 11 of its last 13 reported years, so there is a history but no current dividend. (From the NSE corporate-actions record, read 18 November 2026.) ## What did IPCA Labs management say on the latest results call? On the call for July to September 2026, held on 5 November 2026, IPCA Labs' management guided: FY27 overall business growth 14-16% retained, later referenced as 15-16%. > “In fact, from the current 1,500 crores of the umbrella brand, we are looking at similar growth continuing for the next 3-4 years” > Management, on the call for July to September 2026 ### What management guided - FY27 consolidated operating margin 23% retained, up from 22% initial frame. - Medium-term 2-3 year consolidated uplift 1-1.3pp annually and standalone 1.5pp annually. - Unichem FY27 top-line growth around 10% retained without revision. - Unichem operating margin 11-13% if freight and energy stay elevated. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/2689/Conference Call/CC-Nov26.pdf). (From the call for July to September 2026, 5 November 2026.) ## What to watch in IPCA Labs' next results? When IPCA Labs reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Institutional quarterly run-rate normalizes in H2 versus flagged full-year uplift - check lumpiness and next-year dip warning. Management raised each of these on the latest results call. - Institutional quarterly run-rate normalizes in H2 versus flagged full-year uplift - check lumpiness and next-year dip warning. - Unichem other-expense trajectory eases as flagged freight surge normalizes - check margin path lasts. - Combined US dollar momentum sustains across Ipca and Unichem portfolios - check relative growth gap in next print. ## Which stock lists is IPCA Labs on? IPCA Labs is on 3 of our India lists: Multibagger study list, Small & mid cap stocks and Pharma stocks. - [Multibagger study list Study stage: middle](https://www.sectoralpha.in/multibagger-stocks-india) - [Small & mid cap stocks Size rank in India: 211](https://www.sectoralpha.in/small-cap-stocks-india) - [Pharma stocks Market value: ₹46,540 crore](https://www.sectoralpha.in/sectors/pharma-stocks-india) ## Is IPCA Labs profitable? Ipca Laboratories Ltd earned ₹389 Cr of net profit in the Sep 2026 quarter, +38.4% on the same quarter a year earlier. That is the 10th quarter in a row of profit growth. Full-year FY26 profit was ₹1,184 Cr. Over 10 years profit has grown 29.0% a year on average. The same quarter a year earlier earned ₹281 Cr. The Sep 2026 quarter's profit is 13.4% of that quarter's revenue. For the full year, FY26 profit was ₹1,184 Cr (+50.8% on the year before). Why profit moved: revenue changed +13.8% on a year earlier and the margin moved +1.8 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +133.0% and revenue +11.8%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does IPCA Labs make, and is it growing? Ipca Laboratories Ltd reported ₹2,910 Cr of revenue in the Sep 2026 quarter, +13.8% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 12.8% a year on average. The last full year, FY26, came in at ₹9,599 Cr. Why this happened. The API business was cited as one reason for the raised outlook. New intermediate capacity extends the operating runway beyond Ratlam, while the stated cost pass-through mechanism reduces exposure to input inflation. The driver stops working if API growth normalizes below the broader company growth rate while the new plants remain underutilized. The last four reported quarters add to ₹10,478 Cr. FY26 revenue was ₹9,599 Cr, +7.9% on the year before. Recent pace: the last four quarters grew +11.8% on average, against 12.8% a year over the longer run, so this year is growing at about the same pace as its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +12.0%, against +10.8% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +73.8%, against +49.2% a year (accelerating). ## How much of every ₹100 of sales does IPCA Labs keep? Ipca Laboratories Ltd's operating margin was 23.1% in the Sep 2026 quarter, 1.8 percentage points higher than the same quarter a year ago. Across 13 years it has been between 10.3% and 28.8%. The latest quarter is within that range. Why this happened. The Chronic Therapy Annuity Premium applies because chronic growth exceeded the industry growth rate while acute therapies also remained ahead of the market. This mix can support realization and operating-margin resilience, but it stops working if domestic growth drops below the market for two consecutive quarters. Why the margin moved: operating margin changed +1.8 percentage points on the year while gross margin changed +2.6 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is IPCA Labs' profit turning into cash? Over the last 3 years, 137% of Ipca Laboratories Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹1,142 Cr of operating cash against ₹1,184 Cr of profit. After ₹656 Cr of spending on assets, ₹486 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 137% of profit came in as cash: the cash cycle got 57 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 1.6× depreciation over three years. The next section checks what that spending is building. ## Where does IPCA Labs' cash go? Ipca Laboratories Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 308 days in FY26, up from 251 days in FY21. It spent ₹1,843 Cr on assets over the last 3 years. Customers take 77 days to pay, and stock sits for 353 days on average. At FY26 sales of ₹9,599 Cr, each day of that cycle ties up about ₹26.3 Cr, so roughly ₹8,100 Cr is tied up in the business at any time. FY26: customers took 77 days to pay and stock sat for 353 days, about 11.6 months of sales sitting as stock, for a full cycle of 308 days, longer than FY21's 251. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 353 days. Customers pay about 77 days after that. Suppliers are paid at 122 days. Together that makes the 308-day cycle. Spending on assets: ₹1,843 Cr over the last 3 years, against ₹1,173 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹773 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is IPCA Labs' P/E ratio, and how does it compare with its own history? Ipca Laboratories Ltd's P/E is 33.5×, near the low end of its own history: it has been lower only 35% of the time. Its usual P/E (the middle reading) is 37.1×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹55.28. Why the multiple is where it is: over the past year earnings per share moved +54.7% while the price moved +28.4%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +12.3% a year; about +7.5% a year came from earnings growth and about +4.8 percentage points from the multiple (the market paying more); over 10 years the price moved +21.2% a year; about +32.1% a year came from earnings growth and about −10.9 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. The PEG ratio and its quarterly curve, which only the second data source has, are not shown on this page: its two data sources disagree by up to 5,809% on reported income across 17 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What growth does the IPCA Labs share price assume? Worked out from its price on 11 October 2026, Ipca Laboratories Ltd's share price assumed profit growth of about 21.0% a year. Over the past 10 years its profit actually grew 29.0% a year. Today its P/E is 33.5×, lower than 65% of its own last 11 years. This is a one-day reading, taken on 11 October 2026. Every other number on this page, the multiple included, uses the latest price as of 18 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the IPCA Labs business getting better or worse? Ipca Laboratories Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 17.0% (four quarters to FY26). This is based on 10 quarters of 4 measures, with some gaps. Why it matters: steady growth with healthy returns is how a business compounds over time. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## What is the IPCA Labs story, and has it been checked? Ipca Laboratories Ltd's story is not scored yet against the checks our research set on 22 August 2026. Where it sits in its own cycle: early expansion. Our read, 22 August 2026. Ipca has delivered an export-led earnings step-up and raised FY27 growth and margin guidance, but the current margin is above mid-cycle and Unichem launch guidance has been cut. From the numbers. Earnings… From the price. Price stage 2, week 45, above its 200-day line, relative strength falling. Where they disagree. What is not proven yet. The whole thesis breaks if consolidated operating margin falls below 21% for two consecutive quarters while domestic formulations and APIs both grow below management's FY27 framework, because that would show the current earnings step-up was not durable. The test written in advance. The test written in advance. Reduced product-launch cadence. Measured by: Reduced product-launch cadence Combined annual launches below 7 or no explanation of the revised launch framework by Q2 FY27. by the next result. What the company does. The latest quarter combined faster revenue growth, a higher operating margin, and reported profit growth versus the prior-year quarter. Domestic formulations, APIs and exports are the near-term engines, while Unichem recovery and product launches require delivery rather than another revision. What the surface reading misses. The surface reading is: Reported profit rose sharply from the prior-year quarter. The research reads it further: The profit increase combines higher revenue with a higher operating margin; it is not presented as a below-the-line one-off because the one-off ledger marks the quarter clean. What the surface reading misses. The surface reading is: A 24% operating margin suggests improving profitability. The research reads it further: The cycle-normalized calculation places the margin at the 88th percentile of history versus normalized margin of 18.6%, so current earnings include a high-margin cycle component. Lever 1 · Operating leverage: building. Domestic formulations remain ahead of the market, led by chronic therapies and specialty segments. What proves it keeps working: Domestic chronic and specialty mix. It stops working if Domestic formulation growth trails the industry market for two consecutive quarters. Lever 7 · Consolidation: building. API revenue rose nearly 30% in the latest quarter and Dewas and Wardha capacity is being built. What proves it keeps working: API expansion and new capacity. It stops working if API growth falls below consolidated revenue growth for two consecutive quarters after new capacity begins operations. Lever 10 · New geographies: building. Exports grew faster in the latest quarter, with Europe, Brazil and Asian markets contributing to Unichem's portfolio. What proves it keeps working: Export and Unichem portfolio breadth. It stops working if Export growth falls below domestic growth while European and Brazil portfolio gains fail to persist for two quarters. Lever 12 · New product launch: building. Captive APIs, Europe and Brazil improvement, and Ireland-cost removal are the stated recovery levers. What proves it keeps working: Unichem cost and margin recovery. It stops working if Unichem EBITDA margin remains below 10% through Q3 FY27. Sources: our stock research file (22 August 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did IPCA Labs management deliver what it promised? What Ipca Laboratories Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. Institutional Shipment Benefit Changed · 5 November 2026. Both the June 2026 and August 2026 calls described the Q1 institutional timing benefit as approximately INR40 crores. In November 2026, management instead described the same March-to-April shipment as approximately 25 crore and used that figure to support exceeding the INR300 crore guidance, creating a 15 crore unexplained difference in the one-off benefit underlying the forecast. Product Launch Cadence Cut · 14 August 2026. Prior calls described a substantially higher near-term launch cadence: Feb 2026 referred to 5-7 molecules over 12-15 months, and Jun 2026 indicated 6-8 Ipca products plus at least 5-6 Unichem products in the current financial year. In Aug 2026, management instead described only 7-8 launches combined per year, a material reduction in the product-driven growth pipeline with no explanation of whether the earlier goals were cancelled, delayed, or re-scoped. Unichem Ireland Facility Savings Delayed · 1 June 2026. In the Nov 2025 call, management stated that the closure costs for Unichem's Ireland facility were already settled in Q1 and that the EUR 3.5 to 4 million running overhead would be cut immediately. However, in the Jun 2026 call, management revealed they actually continued operating and incurring EUR 4 to 5 million in overhead for the Ireland facility throughout the entire past financial year (FY26), pushing the realization of these expected savings to FY27 without explaining the execution delay. Unichem Margin and Growth Outlook · 16 February 2026. Management guided in the November 2025 call that Unichem's margins (around 11%) would remain stable and in line with Q2 levels, citing good US growth of 12%. However, in the February 2026 call, they reported a significant deterioration with margins dropping to 8% and base business growth falling to 2%, attributed to lost high-volume business. Earlier call (Nov 2025): “I think over INR60 crores kind of EBITDA margins they have, which is around 11% or so of the second quarter. So, I think overall, their business margins are expected to remain around what is in line with the second quarter”. Later call (Feb 2026): “Overall, Unichem”. Every quote above is taken word for word from the company’s own earnings calls. ## What is IPCA Labs management's track record? Domestic medicine delivery and acknowledged Unichem weakness support a mixed grade. ### Regulatory and governance record The old criminal-procedure excerpt contains opposing counsel’s fraud allegation and questions the magistrate’s directions; it is not a final fraud finding. Current status and materiality are missing. Sources: - [ipca.com](https://www.ipca.com/wp-content/pdf/financials/conferencecall-and-transcripts/transcript-1st-June-2026.pdf) - [indiankanoon.org](https://indiankanoon.org/doc/98785870/) - [ipca.com](https://www.ipca.com/wp-content/pdf/corporate-policy/Policy_on_Related_Party_Transactions.pdf) (Checked 14 October 2026.) ## How much does IPCA Labs earn on its capital? Ipca Laboratories Ltd earned a ROCE of 17% in FY26. That is up from a low of 5% in FY16. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 12.3% net margin and 0.78× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 12.3% net margin × 0.78× asset turnover × 1.53× leverage (assets divided by equity) ≈ 14.7% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 5,809% on reported income across 17 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does IPCA Labs have too much debt? Ipca Laboratories Ltd had ₹809 Cr of borrowings against ₹8,063 Cr of equity in FY26, so its debt is 0.10× its equity. Its operating profit is 25 times its interest bill. Over 5 years borrowings went from ₹265 Cr to ₹809 Cr. Over the last 3 of those years it spent ₹1,843 Cr on assets. Part of the spending on assets is being paid for with borrowed money. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 5,809% on reported income across 17 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the IPCA Labs shareholding pattern? Domestic institutions raised their stake in Ipca Laboratories Ltd by 2.7 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 36.6% of the company. Promoters moved −1.6 points over the same period, to 44.7%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +2.7 points over 8 quarters, to 36.6%; Promoters: −1.6 points over 8 quarters, to 44.7%; Foreign institutions: +0.7 points over 8 quarters, to 11.5%. Why the owners changed: domestic institutions drove it (+2.7 points), with the other side taken by promoters (−1.6 points). They raised their stake step by step. ## How far is IPCA Labs from balance-sheet trouble? For Ipca Laboratories Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does IPCA Labs rank in its industry? 62.4 out of 100, rank 10 of 44 in Pharma - Formulators, with 82% of the evidence available. Ipca Laboratories Ltd scores 62.4 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 10. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 24.5 + 15.7 + 11.7 + 10.5 = 62.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is IPCA Labs compared with? IPCA Labs ranks 10 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 62.4 out of 100. 1. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · losing its lead · Most evidence points up · 78% evidence 75.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.5/35 · Revenue 24.2% · Profit 60.3% · Operating margin change 3 points · 100% evidence Capital efficiency 18.0/25 · ROCE 18.8% (year to Mar 2026) · Operating margin 22.8% · 100% evidence Valuation 15.4/20 · P/E 23.8× · PEG 0.92 · 65% evidence Relative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 31.3% · 1 year 53.6% · 25% evidence · 11 of 12 weeks ahead Exact sum: 30.5 + 18 + 15.4 + 11.9 = 75.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · leader · Most evidence points up · 75% evidence 72.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.1/35 · Revenue 21.1% · Profit 33.3% · Operating margin change 0 points · 95% evidence Capital efficiency 18.0/25 · ROCE 24% (year to Mar 2026) · Operating margin 20.9% · 76% evidence Valuation 10.0/20 · P/E 40.5× · PEG n/a · 15% evidence Relative strength 18.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 17.5% · Strength vs NIFTY 500 (same reading) 33.7% · 1 year 72.4% · 100% evidence · 10 of 12 weeks ahead Exact sum: 26.1 + 18 + 10 + 18.7 = 72.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 75% evidence 68.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.5/35 · Revenue 47.6% · Profit 95.9% · Operating margin change 4 points · 100% evidence Capital efficiency 17.0/25 · ROCE 24.1% (year to Mar 2026) · Operating margin 27.6% · 100% evidence Valuation 6.5/20 · P/E 45.5× · PEG n/a · 50% evidence Relative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 68.2% · 1 year 345.7% · 25% evidence · 9 of 9 weeks ahead Exact sum: 32.5 + 17 + 6.5 + 12.3 = 68.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · losing its lead · Most evidence points up · 87% evidence 67.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 46.3% · Profit 90.1% · Operating margin change 2 points · 100% evidence Capital efficiency 18.8/25 · ROCE 28.4% (year to Mar 2026) · Operating margin 25% · 100% evidence Valuation 8.1/20 · P/E 84.3× · PEG 2.11 · 65% evidence Relative strength 16.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 28.5% · Strength vs NIFTY 500 (same reading) 42.3% · 1 year 144.6% · 70% evidence · 10 of 12 weeks ahead Exact sum: 24 + 18.8 + 8.1 + 16.5 = 67.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 5. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · losing its lead · Most evidence points up · 65% evidence 66.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.8/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.6/25 · ROCE 24.9% (year to Mar 2026) · Operating margin 23.4% · 100% evidence Valuation 10.1/20 · P/E 25.6× · PEG n/a · 50% evidence Relative strength 12.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 13.6% · Strength vs NIFTY 500 (same reading) 27.2% · 1 year 97.1% · 100% evidence · 11 of 12 weeks ahead Exact sum: 21.8 + 21.6 + 10.1 + 12.7 = 66.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · quiet · Most evidence points up · 100% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.1/25 · ROCE 34.5% (year to Mar 2026) · Operating margin 30.6% · 100% evidence Valuation 9.2/20 · P/E 32.4× · PEG 1.91 · 100% evidence Relative strength 5.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -10.2% · Strength vs NIFTY 500 (same reading) 2.4% · 1 year 31.7% · 100% evidence · 8 of 12 weeks ahead Exact sum: 30.3 + 21.1 + 9.2 + 5.1 = 65.7 · What this means: Earnings are strong; relative strength in its sector is -10.2% and the one-year return is 31.7%. 7. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Most evidence points up · 100% evidence 65.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.3/35 · Revenue 13.5% · Profit 27.5% · Operating margin change 2 points · 100% evidence Capital efficiency 15.8/25 · ROCE 13.5% (year to Mar 2026) · Operating margin 27% · 100% evidence Valuation 10.4/20 · P/E 48.3× · PEG 2.64 · 100% evidence Relative strength 12.8/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.4% · Strength vs NIFTY 500 (same reading) 10.8% · 1 year 17.1% · 100% evidence · 4 of 12 weeks ahead Exact sum: 26.3 + 15.8 + 10.4 + 12.8 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 65.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.2/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.5/25 · ROCE 16.9% (year to Mar 2026) · Operating margin 25.9% · 76% evidence Valuation 6.5/20 · P/E 44.8× · PEG n/a · 50% evidence Relative strength 14.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 55.9% · Strength vs NIFTY 500 (same reading) 69.5% · 1 year 325.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.2 + 14.5 + 6.5 + 14.1 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · leader · Evidence leans up · 85% evidence 64.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 19.7% · Profit 32.7% · Operating margin change 5 points · 100% evidence Capital efficiency 12.1/25 · ROCE 12.6% (year to Mar 2026) · Operating margin 21.6% · 100% evidence Valuation 14.5/20 · P/E 24.3× · PEG 1.28 · 100% evidence Relative strength 11.6/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 24.7% · 1 year 15.9% · 25% evidence · 9 of 12 weeks ahead Exact sum: 25.8 + 12.1 + 14.5 + 11.6 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. Ipca Laboratories Ltd this page IPCALAB · leader · Evidence leans up · 82% evidence 62.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.5/35 · Revenue 12% · Profit 73.8% · Operating margin change 2 points · 95% evidence Capital efficiency 15.7/25 · ROCE 17% (year to Mar 2026) · Operating margin 23.1% · 76% evidence Valuation 11.7/20 · P/E 33.5× · PEG n/a · 50% evidence Relative strength 10.5/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.6% · Strength vs NIFTY 500 (same reading) 9.9% · 1 year 28.4% · 100% evidence · 11 of 12 weeks ahead Exact sum: 24.5 + 15.7 + 11.7 + 10.5 = 62.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · losing its lead · Evidence leans up · 70% evidence 61.2 out of 100 Growth Capital Valuation Relative 12. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · turning · Evidence leans up · 75% evidence 59.2 out of 100 Growth Capital Valuation Relative 13. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans up · 100% evidence 58.9 out of 100 Growth Capital Valuation Relative 14. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · breaking out · Evidence leans up · 73% evidence 58.3 out of 100 Growth Capital Valuation Relative 15. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Evidence leans up · 90% evidence 57.2 out of 100 Growth Capital Valuation Relative 16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 75% evidence 56.8 out of 100 Growth Capital Valuation Relative 17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.0 out of 100 Growth Capital Valuation Relative 18. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · turning · Evidence leans up · 82% evidence 55.8 out of 100 Growth Capital Valuation Relative 19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · quiet · Evidence leans up · 90% evidence 55.2 out of 100 Growth Capital Valuation Relative 20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 83% evidence 54.7 out of 100 Growth Capital Valuation Relative 21. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Evidence leans up · 63% evidence 54.3 out of 100 Growth Capital Valuation Relative 22. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · breaking out · Evidence leans up · 90% evidence 54.1 out of 100 Growth Capital Valuation Relative 23. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · losing its lead · Evidence leans up · 75% evidence 53.3 out of 100 Growth Capital Valuation Relative 24. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 82% evidence 52.3 out of 100 Growth Capital Valuation Relative 25. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · breaking out · Evidence leans up · 90% evidence 51.5 out of 100 Growth Capital Valuation Relative 26. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Evidence leans up · 90% evidence 50.6 out of 100 Growth Capital Valuation Relative 27. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 68% evidence 49.1 out of 100 Growth Capital Valuation Relative 28. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 82% evidence 48.3 out of 100 Growth Capital Valuation Relative 29. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 45.8 out of 100 Growth Capital Valuation Relative 30. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.8 out of 100 Growth Capital Valuation Relative 31. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 74% evidence 42.8 out of 100 Growth Capital Valuation Relative 32. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · basing · Evidence leans down · 90% evidence 42.7 out of 100 Growth Capital Valuation Relative 33. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 90% evidence 41.5 out of 100 Growth Capital Valuation Relative 34. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.8 out of 100 Growth Capital Valuation Relative 35. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 90% evidence 38.9 out of 100 Growth Capital Valuation Relative 36. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · turning · Too little evidence to rank firmly · 52% evidence 37.8 out of 100 Growth Capital Valuation Relative 37. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 67% evidence 34.4 out of 100 Growth Capital Valuation Relative 38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · quiet · Most evidence points down · 100% evidence 34.2 out of 100 Growth Capital Valuation Relative 39. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Most evidence points down · 90% evidence 31.9 out of 100 Growth Capital Valuation Relative 40. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · breaking out · Most evidence points down · 100% evidence 30.4 out of 100 Growth Capital Valuation Relative 41. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · quiet · Most evidence points down · 100% evidence 27.9 out of 100 Growth Capital Valuation Relative 42. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · basing · Most evidence points down · 100% evidence 22.7 out of 100 Growth Capital Valuation Relative 43. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.4 out of 100 Growth Capital Valuation Relative 44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · quiet · Too little evidence to rank firmly · 36% evidence 38.3 out of 100 Growth Capital Valuation Relative Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to IPCA Labs in size? IPCA Labs is the 12th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Glenmark Pharmaceuticals, Alkem Laboratories and Biocon. Just below it: Emcure Pharmaceuticals, Ajanta Pharma and J B Chemicals & Pharmaceuticals. ### Pharma - Formulators companies close in size 1. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) ₹74,679 crore 2. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ₹62,443 crore 3. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) ₹58,987 crore 4. Ipca Laboratories Ltd ₹47,039 crore 5. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) ₹44,294 crore 6. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) ₹40,910 crore 7. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) ₹38,677 crore [All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies) ### Companies close in size in other industries 1. [Sundaram Finance Ltd](https://www.sectoralpha.in/stocks/sundaram-finance-ltd) ₹47,725 crore · Finance & Investments - CV Finance 2. [Authum Investment & Infrastructure Ltd](https://www.sectoralpha.in/stocks/authum-investment-infrastructure-ltd) ₹47,115 crore · Finance & Investments - Others 3. Ipca Laboratories Ltd ₹47,039 crore 4. [UPL Ltd](https://www.sectoralpha.in/stocks/upl-ltd) ₹46,584 crore · Pesticides/Agrochemicals 5. [HDB Financial Services Ltd](https://www.sectoralpha.in/stocks/hdb-financial-services-ltd) ₹46,486 crore · Conglomerate Backed NBFC ## What else do people ask about IPCA Labs? ### What were IPCA Labs's latest quarterly results? Ipca Laboratories Ltd reported revenue of ₹2,910 Cr and net profit of ₹389 Cr for the Sep 2026 quarter. Revenue rose 13.8% and profit rose 38.4% compared with a year earlier. Earnings per share were ₹14.79. The operating margin was 23.1%, 1.8 percentage points higher than a year earlier (as of 18 November 2026). ### What is IPCA Labs's market cap? Ipca Laboratories Ltd's market capitalisation is ₹47,039 Cr at a share price of ₹1,854.10. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026). ### How is IPCA Labs performing? Ipca Laboratories Ltd's share price has been rising for 45 weeks. In its latest quarter, revenue rose 13.8% and profit rose 38.4% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 2 weeks running (as of 18 November 2026). ### Will IPCA Labs's share price go up? This page does not forecast Ipca Laboratories Ltd's share price. What it shows instead: the share price is ₹1,854.10, and it has been rising for 45 weeks. Its P/E of 33.5× is higher than 35% of its own last 11 years (as of 18 November 2026). ### Who owns IPCA Labs? Promoters own 44.7% of Ipca Laboratories Ltd, foreign institutions 11.5%, domestic institutions 36.6% and the public 7.2% (latest quarter). The biggest change over the last two years: Domestic institutions raised their stake by 2.7 percentage points over 8 quarters (as of 18 November 2026). ### Where is IPCA Labs in its business cycle? Ipca Laboratories Ltd's FY26 operating margin was 20.7%, against a 13-year range of 10.3% to 28.8%. The latest quarter was 23.1%, the middle of its own range, neither a peak nor a low. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026). ### What could break the IPCA Labs story? The main question: yearly earnings per share moved +54.7% while the share price moved +28.4%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026). ### Is IPCA Labs a stock worth studying right now? What the numbers show: Ipca Laboratories Ltd's results are improving, while its P/E is near the low end of its own history over 11 years, higher than only 35% of past readings. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026). ### Is there a IPCA Labs share price forecast for 2026? What management itself guided: FY27 overall business growth 14-16% retained, later referenced as 15-16%. ### Where does this page get IPCA Labs' management information? From IPCA Labs' results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results. ## Lists - Multibagger study list: https://www.sectoralpha.in/multibagger-stocks-india - Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india - Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india This is research, not advice. We’re not SEBI-registered.